Board of Trustees of The Leland Stanford Junior University’s LENZ Therapeutics LENZ Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,438	Closed	-$1.74M	–	27
2024 Q2	$1.74M	Hold	100,438	–	–	0.12%	13
2024 Q1	$2.24M	Sell	100,438 -1	-0%	-$21	0.2%	12
2023 Q4	$1.84M	Hold	100,439	–	–	0.12%	17
2023 Q3	$1.74M	Hold	100,439	–	–	0.13%	11
2023 Q2	$1.83M	Hold	100,439	–	–	0.18%	14
2023 Q1	$1.72M	Buy	100,439 +34,827	+53%	+$563K	0.16%	18
2022 Q4	$1.52M	Sell	65,612 -34,827	-35%	-$807K	0.15%	17
2022 Q3	$2.23M	Hold	100,439	–	–	0.14%	25
2022 Q2	$1.93M	Hold	100,439	–	–	0.13%	17
2022 Q1	$3.58M	Hold	100,439	–	–	0.2%	13
2021 Q4	$8.74M	Hold	100,439	–	–	0.55%	13
2021 Q3	$11.5M	Sell	100,439 -90	-0.1%	-$13.3K	0.86%	12
2021 Q2	$21.6M	Buy	+100,529	New	+$17.5M	2.02%	9

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's LENZ Position: Q3 2024 in Review

Board of Trustees of The Leland Stanford Junior University sold out of LENZ Therapeutics (LENZ) in Q3 2024, closing a stake of 100,438 shares — an estimated $1.74M sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in LENZ in Q2 2021 and held it in 13 quarters. The position peaked at $21.6M in Q2 2021. 78 funds tracked by Wall St. Rank hold LENZ as of Q3 2024.

Board of Trustees of The Leland Stanford Junior University reported no remaining LENZ Therapeutics position as of Q3 2024 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 100,438 LENZ Therapeutics shares in Q3 2024, an estimated $1.74M.
Board of Trustees of The Leland Stanford Junior University first reported a position in LENZ Therapeutics in Q2 2021 and held it in 13 quarters.
Board of Trustees of The Leland Stanford Junior University's LENZ Therapeutics position peaked at $21.6M in Q2 2021.
78 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2024.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q3 2024, filed 12 Nov 2024.